MedTrace Logo

BV-AVD-R Treatment Children Hodgkin's Lymphoma

NCT06201507 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2024-01-12

No results posted yet for this study

Summary

The goal of this clinical trial is to use modified Brentuximab Vedotin+doxorubicin+vinblastine+dacarbazine+Rituximab(BV-AVD-R) regimen in Chinese Classical Hodgkin's Lymphoma(HL) children. The main questions it aims to answer are:

* \[Overall Response Rate(ORR) :Complete Response(CR)+Partial Response(PR)\]
* \[progression-free survival (PFS), event-free survival (EFS) and overall survival (OS) at 6 months and 1 year.\] Participants will be given modified BV-AVD-R regimen according to rapid early responders (RER) or slow early responders (SER) after 2 cycles.

Conditions

Interventions

DRUG

Brentuximab vedotin

Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)

DRUG

Rituximab

Days: 2 and 16 Dose: 375 mg/m2/dose.

DRUG

Doxorubicin

Days: 1 and 15 Dose: 25 mg/m2/dose.

DRUG

Vincristine

1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).

DRUG

Dacarbazine

375 mg/m2 will be administered on days 1 and 15

Sponsors & Collaborators

  • Beijing Children's Hospital

    lead OTHER

Principal Investigators

  • Yanlong Duan · Beijing Children Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06201507 on ClinicalTrials.gov